Notice for ravulizumab (Alexion Pharmaceuticals Australasia Pty Ltd)
Active ingredients
ravulizumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
solution for intravenous infusion
Indication
For the treatment of primary immunoglobulin A nephropathy (IgAN)
Therapeutic area
Nephrology